Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Blood (2022) 140 (21): 2228–2247.

https://doi.org/10.1182/blood.2022015853

Published: 2022

Includes: Supplemental data

Journal Articles

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Rami Komrokji, Virginia Volpe, Onyee Chan, Najla Al Ali, David Swoboda, Andrew Kuykendall, Eric Padron, David A. Sallman

Blood (2021) 138 (11): 989–992.

https://doi.org/10.1182/blood.2021010831

Published: 2021

Journal Articles

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Mohammad O Hussaini, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD MS, David A. Sallman, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140885

Published: 2020

Journal Articles

Clinical Characteristics and Outcomes of Patients with Large Granular Lymphocytic Leukemia Treated with Methotrexate, Cyclophosphamide or Cyclosporine. a Large Single Institutional Retrospective Analysis

Ankita Tandon, DO, Ning Dong, MD, Yumeng Zhang, MD, Emilie Wang, MD, Todd C. Knepper, PharmD, Haipeng Shao, MD, Ling Zhang, MD, Leidy Isenalumhe, MD, Rami Komrokji, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-141701

Published: 2020

Journal Articles

SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Onyee Chan, MD, Najla Al Ali, MD, David A. Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141960

Published: 2020

Journal Articles

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Quinto J Gesiotto, MD, David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Chetasi Talati, MD, Kendra L. Sweet, MD MS, Jeffrey E. Lancet, MD, Rami Komrokji, MD, David A. Sallman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140861

Published: 2020

Journal Articles

Large Granular Lymphocytic Leukemia with Coexisting Malignancies

Ning Dong, MD, Leidy Isenalumhe, MD, Yumeng Zhang, MD, Franco Castillo Tokumori, MD, Todd C. Knepper, PharmD, Rami Komrokji, MD, Ling Zhang, MD, Haipeng Shao, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136796

Published: 2020

Journal Articles

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

John Mascarenhas, MD, Heidi E. Kosiorek, MS, Lilian Varricchio, PhD, Rupali Bhave, MD, Andrew T. Kuykendall, MD, Rami Komrokji, MD, Aaron T. Gerds, MDMS, Jeanne M. Palmer, MD, Amelia R. Gabler, Lonette Sandy, Anna Rita Migliaccio, PhD, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Maureen O'Connor-McCourt, PhD, Gilles Tremblay, PhD, Paul I. Nadler, MD, Amylou C. Dueck, PhD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-140830

Published: 2020

Journal Articles

Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis

Franco Castillo Tokumori, MD, Chetasi Talati, MD, Najla E. Al Ali, David A. Sallman, MD, Seongseok Yun, MDPhD, Kendra L. Sweet, MD MS, Eric Padron, MD, Jeffrey E. Lancet, MD, Rami Komrokji, MD, Andrew T. Kuykendall, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-140145

Published: 2020

Journal Articles

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140317

Published: 2020

Journal Articles

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD PhD MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, MD MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-139815

Published: 2020

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Pierre Fenaux, MD PhD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Carlo Finelli, Mario Cazzola, MD, Osman Ilhan, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Uwe Platzbecker, MD, Rami Komrokji

Blood (2019) 134 (Supplement_1): 4243.

https://doi.org/10.1182/blood-2019-123048

Published: 2019

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

Journal Articles

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Blood (2017) 130 (13): 1514–1522.

https://doi.org/10.1182/blood-2017-06-788497

Published: 2017

Includes: Supplemental data

Journal Articles

Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis

Chetasi Talati, Ling Zhang, Ghada Shaheen, Andrew Kuykendall, Markus Ball, Qing Zhang, Jeffrey E. Lancet, Kenneth S. Zuckerman, Alan F. List, Rami Komrokji, Lynn Moscinski, Eric Padron

Blood (2017) 129 (13): 1881–1883.

https://doi.org/10.1182/blood-2016-12-753210

Published: 2017

Journal Articles

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

Blood (2016) 128 (25): 2960–2975.

https://doi.org/10.1182/blood-2016-07-730556

Published: 2016

Includes: Supplemental data

Journal Articles

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Blood (2015) 125 (12): 1857–1865.

https://doi.org/10.1182/blood-2014-10-607341

Published: 2015

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

Clinical Characteristics and Outcomes of Patients with Large Granular Lymphocytic Leukemia Treated with Methotrexate, Cyclophosphamide or Cyclosporine. a Large Single Institutional Retrospective Analysis

SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Large Granular Lymphocytic Leukemia with Coexisting Malignancies

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only